| Name | Shares allotted | % of global offering | % of post-IPO shares | Lock-up |
|---|---|---|---|---|
| Lake Bleu Innovation Healthcare Master Fund Limited | 0 | 0.93% | — | 6 months |
| Lake Bleu Prime Healthcare Master Fund Limited | 0 | 1.64% | — | 6 months |
| LBC HK Opportunity Fund Limited | 0 | 1.72% | — | 6 months |
| OrbiMed Funds | 0 | 5.35% | — | 6 months |
| RTW Funds | 0 | 6.43% | — | 6 months |
| TruMed | 0 | 5.36% | — | 6 months |
| UBS Asset Management (Singapore) Ltd. | 0 | 4.28% | — | 6 months |
| Vivo Funds | 0 | 4.28% | — | 6 months |
| 富国基金管理有限公司 | 0 | 3.43% | — | 6 months |
| 富国资产管理(香港)有限公司 | 0 | 0.86% | — | 6 months |
| 汇添富基金管理股份有限公司 | 0 | 0.86% | — | 6 months |
| 汇添富资产管理(香港)有限公司 | 0 | 3.43% | — | 6 months |
| 中信证券国际资本管理有限公司 | 0 | 4.28% | — | 6 months |
| Rank | % of international placing | % of global offering |
|---|---|---|
| 前1名 | — | — |
The IPO of 劲方医药-B recorded an extreme oversubscription ratio of 2,662.79x, indicating frenzy-level retail demand. A hit rate of just 12.76% reflects severe allocation scarcity, and the offer price was fixed at HK$20.39 with no range to anchor expectations. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Without detailed tier distribution data, specific inefficiencies like 甲尾 vs 乙头 cannot be assessed. Reallocation from the international tranche was triggered, suggesting strong retail demand overwhelmed the 8.7% initial public offer portion, but the impact on allocation tiers is unclear. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice. Data may contain errors or omissions; verify against official filings.)
Official demographic data for subscribed investors is unavailable. For biotech listings with such extreme oversubscription, a high proportion of mainland retail participation is typical, but no breakdown is provided. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
This page shows allotment analysis for Genfleet-B (02595): one-lot hit rate, Pool A/B allotment distribution, oversubscription multiple, and grey-market and first-day performance. Data is parsed from the HKEX allotment results announcement. How allotment rates and clawback work is explained in How Hong Kong IPO Allotment Rates Work.

